论文部分内容阅读
血管内皮生长因子受体Ⅱ (激酶功能区受体 ,KDR)是介导血管内皮生长因子 (VEGF)在肿瘤新生血管形成中发挥功能的主要受体 ,以KDR为靶 ,通过抑制VEGF与KDR的相互作用来抑制血管生长从而达到治疗肿瘤目的已经成为肿瘤治疗的新途径。本文从抗KDR的单克隆抗体、酪氨酸激酶小分子抑制剂、KDR的小肽抑制剂、核酸抑制物和导向制剂等几个方面综述了以KDR为靶治疗肿瘤的基础和临床现状及研究进展 ,探讨不同各种方法的优势与不足 ,以期在临床实施中选择合适的方法进行KDR靶向的肿瘤治疗。
Vascular endothelial growth factor receptor Ⅱ (KDR) is the main receptor that mediates the function of vascular endothelial growth factor (VEGF) in neovascularization of tumor. KDR is targeted to inhibit the expression of VEGF and KDR Interaction to inhibit the growth of blood vessels in order to achieve the purpose of cancer treatment has become a new way of cancer treatment. This review summarizes the basic and clinical status and progress of KDR-targeted tumors from anti-KDR monoclonal antibodies, small tyrosine kinase inhibitors, small peptide inhibitors of KDR, nucleic acid inhibitors and targeting agents Progress, to explore the advantages and disadvantages of different methods in order to select the appropriate method in clinical implementation of KDR-targeted cancer treatment.